RANDOMIZED, CONTROLLED, OPEN, MULTICENTRIC CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A COMBINATION OF ANTI-TUBERCULOUS DRUGS BASED ON HIGH DOSE RIFAMPICIN, HIGH DOSE MOXIFLOXACIN AND LINEZOLID IN PATIENTS WITH BACILLIFEROUS PULMONARY TUBERCULOSIS (RML-TB).
This study is a research project looking into new ways to treat a specific type of lung tuberculosis where bacteria are still present in a person's spit. It's called "RML-TB" for short. The main goal is to see how well different combinations of anti-tuberculosis medicines work, especially high doses of rifampicin and moxifloxacin, along with linezolid. Researchers also want to understand how safe these new combinations are by tracking any side effects. This is a "Phase II" study, which means it's an early step in testing new treatments to gather initial information about their effectiveness and safety before moving on to larger studies. The study involves adults aged 18 and older, both men and women.
At a glance
What is this study about?
This study is about finding better treatments for a type of lung infection called tuberculosis (TB). Specifically, it's for people who have "bacilliferous pulmonary tuberculosis," which means the TB bacteria are still found in their spit, even after they might have started standard treatment. Doctors and scientists are always looking for ways to make treatments more effective and safer, especially for diseases like TB that can be hard to get rid of completely.
The researchers in this study are testing new combinations of medicines that are already used to treat TB. They are looking at doses that might be higher than usual for some of these drugs, like rifampicin and moxifloxacin, and combining them with another drug called linezolid. The main questions they want to answer are: how well do these new combinations kill the TB bacteria in a patient's spit, and how safe are they for patients to take?
This is an important step in developing new treatments. By finding out if these drug combinations are effective and what side effects they might cause, the study helps doctors understand if these could become better options for patients with this form of TB in the future. It also aims to understand how patients feel during treatment and how the new treatments compare in terms of cost and patient well-being.
Key takeaways
- This study evaluates new drug combinations for lung tuberculosis.
- It focuses on patients whose spit samples still show TB bacteria.
- The study aims to check how well the treatments work and their safety.
- It's an early-stage study to gather initial information.
- Participation involves taking study drugs and regular health checks.
Who may be eligible?
To join this study, you must be at least 18 years old. Both men and women are welcome to participate. The study is specifically for people who have a type of lung tuberculosis where the bacteria are still present in their spit samples.
There might be other health conditions or medications that would prevent someone from joining, as is common with all clinical trials. Your doctor will carefully review all your medical information to see if this study is suitable for you.
It's important that you understand what the study involves and are willing to follow the study plan closely, including taking the medications as instructed and attending all scheduled appointments.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you at least 18 years old?
- Do you have lung tuberculosis with bacteria in your spit?
- Are you willing to take study medications as instructed?
- Can you attend regular clinic appointments for checks and tests?
What does participation involve?
If you decide to join this study, you would be assigned to receive one of the experimental drug combinations being tested. You would take these medications as prescribed by the study team. Throughout the study, you would have regular visits to the clinic so doctors can monitor your health, check for side effects, and see how well the treatment is working. This will involve giving spit (sputum) samples regularly to check for TB bacteria, having blood tests, and potentially other examinations.
The doctors will also ask you questions about how you are feeling and your overall quality of life during the treatment. The entire study participation, including the treatment period and follow-up, will be explained in detail before you make a decision to join. You will be monitored closely for about 8 weeks to see the initial effects of the treatment and any side effects.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What is the main goal of this study?
The main goal is to see if new combinations of existing TB medicines work better and are safe for people with a specific type of lung tuberculosis.
Who can take part in this study?
Adults aged 18 and over, both men and women, who have lung tuberculosis with bacteria in their spit samples, may be able to join.
Will I receive new medications?
You will receive combinations of medications, some of which are existing TB drugs, but they might be given in new doses or combinations not yet widely used.
How long will I be in the study?
The main treatment and observation period for the primary results is about 8 weeks after starting treatment, with follow-up appointments after that.
What do I need to do if I join?
You'll need to take the study medications, attend regular clinic visits, provide spit and blood samples, and answer questions about your health.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.